{
    "symbol": "ABUS",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-04 15:06:03",
    "content": " second initial data from both the Phase IIa combination trial of 729 interferon and NUC therapy and the triple combination trial with Assembly's vebicorvir; third, we expect to complete the IND-enabling studies for both AB-101, our oral PD-L1 inhibitor and AB-161 our oral RNA destabilizer; and fourthly, we expect to advance into IND-enabling studies, a clinical candidate that inhibits the SARS-CoV-2 nsp5 main protease. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}